Relationship between tumor size and metastatic site in patients with stage IV non-small cell lung cancer: A large SEER-based study

Qinge Shan¹,²,* Yanling Fan³,* Jun Guo², Xiao Han², Haiyong Wang² and Zhehai Wang²

¹ School of Medicine and Life Sciences, University of Jinan-Shandong Academy of Medical Sciences, Jinan, Shandong, China
² Department of Internal Medicine-Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, China
³ Department of Haematology and Oncology, Jinxiang People’s Hospital, Jinxiang Hospital Affiliated with Jining Medical University, Jining, Shandong, China

* These authors contributed equally to this work.

ABSTRACT

**Objective.** To analyze the relationship between tumor size and metastatic site in stage IV NSCLC patients.

**Methods.** A total of 40,196 stage IV NSCLC patients from 2010 to 2015 were screened by SEER database. Chi-square test was used to compare the characteristics of clinical variables. At the same time, multivariate Logistic regression analysis was used to evaluate the relationship between tumor size and organ metastasis.

**Results.** Regardless of tumor size, the proportion of bone metastasis and lung metastasis was higher and similar in patients with squamous cell carcinoma, while in patients with adenocarcinoma, bone metastasis accounted for the highest proportion. We found that whether the metastatic site was bone, brain, liver or lung, the proportion of patients with a tumor size of 3–7 cm was the highest. Multivariate regression analysis demonstrated that patients with a tumor size of 3–7 cm and a tumor size ≥7 cm were more likely to develop brain metastasis and lung metastasis compared with patients with a tumor size ≤3 cm (all P < 0.001), which meant the larger the tumor, the greater the risk of brain or lung metastasis. At the same time, the results indicated that patients with a tumor size of 3–7 cm had a tendency to develop liver metastasis (P = 0.004), while the statistical significance was not found for patients with a tumor size ≥7 cm (P = 0.524). The results also revealed that patients with a tumor size of 3–7 cm had no significant difference to develop bone metastasis (P = 0.116), while the statistical significance was found for patients with a tumor size ≥7 cm (P < 0.001).

**Conclusions.** There was statistical significance between tumor size and metastatic site in patients with stage IV NSCLC. For brain or lung metastasis, the larger the tumor, the higher the risk of brain or lung metastasis. For liver metastasis, patients with a tumor size of 3–7 cm were more prone to develop liver metastasis. For bone metastasis, patients with a tumor size ≥7 cm were more likely to have bone metastasis.

Subjects Global Health, Oncology
Keywords Non-small cell lung cancer, Metastatic site, Metastasis, Tumor size, SEER
INTRODUCTION

Lung cancer is one of the most common malignancies and the leading cause of cancer death (Siegel, Miller & Jemal, 2018). The size, type and precise stage of the tumor determines the choice of treatment (Molina et al., 2008), which is beneficial for surgery, chemotherapy, radiotherapy and targeted therapy for the treatment of lung cancer (Cancer Council Australia Lung Cancer Guidelines Working Party, 2016). About 85% of lung cancer patients were diagnosed with non-small cell lung cancer (NSCLC), and approximately 40% were diagnosed with metastatic disease at the time of onset. The most common distant metastatic sites included the brain, liver, adrenal gland and bone (Govindan et al., 2006; Morgensztern et al., 2009; Lee et al., 2016). About 30% to 40% of NSCLC patients had bone metastasis during the course of their disease, and more than 60% of them had bone lesions at the initial diagnosis (Saad et al., 2007; Tsuya et al., 2007). Saad et al. (2008) showed that about 10% of NSCLC patients developed brain metastasis at the initial diagnosis, and 40–50% of NSCLC patients developed brain metastasis during the course of the disease. A retrospective study of 409 patients with stage IV non-small cell lung cancer showed that patients with liver metastasis had lower overall survival (OS) (Badawy et al., 2018).

Tumor size was a known prognostic factor for many cancers, including NSCLC. In most cases, larger tumors have poor prognosis (Motta et al., 1999). In a large clinical staging series (using the 6th edition TNM staging system), survival rates for patients with clinical T1 disease were significantly higher than those with T2 disease (HR 1.48, \( P < 0.0001 \)). At the same time, the above study also demonstrated the survival of patients in clinical T1 group was significantly better than that in T 2-4 group (Shepherd et al., 2007).

Currently, few studies have focused on the relationship between tumor size and metastatic site in NSCLC patients. Therefore, this study retrospectively analyzed the correlation between tumor size and metastatic site in stage IV NSCLC patients.

MATERIALS & METHODS

Patient selection

The Surveillance Epidemiology and End Results (SEER) database was used to screened out appropriate patients with stage IV NSCLC according to the 7th TNM staging system (Surveillance, Epidemiology, and End Results, 2018). The SEER*Stat 8.3.5 software was used to screen stage IV NSCLC patients between 2010 and 2015. Patients included should meet the following criteria: microscopic confirmation; only one measurable primary tumor; and bone, brain, liver, or lung metastasis include at least one. The variables including age, race, sex, histology, tumor size, N stage, metastasis sites should have clear information. In addition, the histologic types of this study included only adenocarcinoma and squamous cell carcinoma.

Ethical evaluation

Our study was approved by the ethics committee of the Shandong Cancer Hospital. Personally identifiable information was not involved therefore no informed consent was required.
Statistical analysis
A chi-square test was used to compare the characteristics of clinical variables. At the same
time, multivariate Logistic regression analysis was used to evaluate the relationship between
tumor size and organ metastasis. All statistical analyses were conducted using SPSS 22.0
(SPSS, Chicago, IL, USA) software package. It was considered statistically significant when
\( p \)-value \( \leq 0.05 \) and all \( p \)-values were two-tailed.

RESULTS
Patient demographics
According to study exclusion and inclusion criteria, a total of 40,196 stage IV NSCLC
patients were enrolled. The cohort in our study included 18,197 (45.3%) female and 21,999
(54.7%) male patients, of whom 59.9% were over 65 years old. Most patients were of
white racial background (76.9%, \( n = 30,894 \)). Nearly three-quarters of the patients had
a pathological type of adenocarcinoma (\( n = 29,269 \)) and the rest were squamous cell
carcinoma (\( n = 10,927 \)). Patients with a tumor size of 3–7 cm accounted for more than
half of the cohort (\( n = 21,266 \)), followed by patients with a tumor size \( \leq 3 \) cm (28.7%),
and patients with a tumor size \( \geq 7 \) cm (18.4%) at least, accounting for about one-fifth of
the total. Among them, patients with bone metastasis, brain metastasis, liver metastasis
and lung metastasis were 15,687 (39%), 11,048 (27.5%), 6,643 (16.5%), 12,760 (31.7%),
respectively. Detailed patient data were summarized in Table 1.

Proportional distribution between tumor size and metastatic site
The Fig. 1 showed the proportion of different metastatic sites in patients with a particular
tumor size, as well as the proportion of different tumor sizes in patients with specific
metastatic site. Firstly, we analyzed the percentage of different metastatic sites in patients
with fixed tumor size in all patients (Fig. 1A). It could be seen from the histogram that,
regardless of the size of the tumor, the number of overall patients with bone metastasis was
the largest, followed by lung metastasis and brain metastasis, and liver metastasis was the
least. Secondly, we analyzed the subgroup of two different pathological types of NSCLC
patients. For patients with squamous cell carcinoma (Fig. 1C), regardless of tumor size, the
higher proportion was bone metastasis and lung metastasis, and the proportion was similar,
while the lower proportion was brain metastasis and liver metastasis, and the proportion
was almost equal. For patients with adenocarcinoma (Fig. 1E), regardless of the size of the
tumor, the highest proportion was in patients with bone metastasis and the least in patients
with liver metastasis. In addition, we exchanged horizontal and vertical coordinates for
the same analysis. We first analyzed the proportion of different tumor sizes in patients
with specific metastatic site in all patients. We could find that whether the metastatic site
was bone, brain, liver or lung, the proportion of overall patients with a tumor size of 3–7
\( \text{cm} \) was the highest, accounting for more than half, and the proportion of patients with
a tumor size \( \geq 7 \) \( \text{cm} \) was the lowest, accounting for less than 20% (Fig. 1B). Regardless
of the metastasis site, the proportion of tumor size of 3 to 7 \( \text{cm} \) was the highest and that
of tumor size \( \leq 3 \) \( \text{cm} \) was the lowest in patients with squamous cell carcinoma (Fig. 1D).
Similarly, regardless of the metastasis site, patients with a tumor size of 3–7 \( \text{cm} \) accounted
Table 1  Characteristics of Patients from SEER Database according to different variables.

| Variables          | Number | %    |
|--------------------|--------|------|
| **Age**            |        |      |
| <65                | 16,128 | 40.1 |
| ≥65                | 24,068 | 59.9 |
| **Race**           |        |      |
| White              | 30,894 | 76.9 |
| Black              | 5,477  | 13.6 |
| Others             | 3,825  | 9.5  |
| **Sex**            |        |      |
| Female             | 18,197 | 45.3 |
| Male               | 21,999 | 54.7 |
| **Histology**      |        |      |
| Adenocarcinoma     | 29,269 | 72.8 |
| Squamous           | 10,927 | 27.2 |
| **Tumor size**     |        |      |
| ≤3 cm              | 11,541 | 28.7 |
| 3–7 cm             | 21,266 | 52.9 |
| ≥7 cm              | 7,389  | 18.4 |
| **N stage**        |        |      |
| N0                 | 9,737  | 24.2 |
| N1                 | 3,301  | 8.2  |
| N2                 | 18,565 | 46.2 |
| N3                 | 8,593  | 21.4 |
| **Bone metastasis**|       |      |
| Yes                | 15,687 | 39.0 |
| No                 | 24,509 | 61.0 |
| **Brain metastasis**|     |      |
| Yes                | 11,048 | 27.5 |
| No                 | 29,148 | 72.5 |
| **Liver metastasis**|    |      |
| Yes                | 6,643  | 16.5 |
| No                 | 33,553 | 83.5 |
| **Lung metastasis**|       |      |
| Yes                | 12,760 | 31.7 |
| No                 | 27,436 | 68.3 |

for the highest proportion of patients with adenocarcinoma, and the lowest proportion was ≥7 cm (Fig. 1F).

**Relationship between tumor size and metastatic site**

To further explore the relationship between tumor size and metastatic sites, we performed a multivariate regression analysis (Table 2). The results showed that patients with a tumor size of 3–7 cm and a tumor size ≥7 cm were more likely to develop brain metastasis and lung metastasis compared with patients with a tumor size ≤3 cm (all \( P < 0.001 \)), which
meant the larger the tumor, the greater the risk of brain or lung metastasis. Interestingly, compared with patients with a tumor size ≤3 cm, patients with a tumor size of 3–7 cm had a tendency to develop liver metastasis ($P = 0.004$), while the statistical significance was not found for patients with a tumor size ≥7 cm ($P = 0.524$). In addition, compared with patients with a tumor size ≤3 cm, patients with a tumor size of 3–7 cm had no significant difference to develop bone metastasis ($P = 0.116$), while the statistical significance was found for patients with a tumor size ≥7 cm ($P < 0.001$).
### Table 2 Multivariate Logistic regression analyses to analyze the relationship between different variables and metastatic site.

| Variables | Bone metastasis | Brain metastasis | Liver metastasis | Lung metastasis |
|-----------|-----------------|------------------|------------------|-----------------|
|           | HR (95% CI)     | P                | HR (95% CI)     | P               | HR (95% CI)     | P               | HR (95% CI)     | P               |
| Age       |                 |                  |                 |                 |
| <65       | Reference       | <0.001           | Reference       | <0.001          | Reference       | 0.018           | Reference       | <0.001          |
| ≥65       | 0.887 (0.850–0.924) | <0.001          | 0.552 (0.527–0.578) | <0.001          | 0.936 (0.887–0.989) | 0.018           | 1.232 (1.179–1.287) | <0.001          |
| Race      |                 |                  |                 |                 |
| White     | Reference       | <0.001           | Reference       | <0.001          | Reference       | 0.020           | Reference       | <0.001          |
| Black     | 0.851 (0.801–0.904) | <0.001          | 0.867 (0.811–0.928) | 0.057          | 0.892 (0.824–0.966) | 0.005           | 1.075 (1.010–1.144) | 0.024          |
| Others    | 1.041 (0.971–1.115) | 0.259           | 1.079 (1.001–1.162) | 0.390          | 0.983 (0.897–1.077) | 0.710           | 1.234 (1.149–1.325) | <0.001          |
| Sex       |                 |                  |                 |                 |
| Female    | Reference       | <0.001           | Reference       | <0.001          | Reference       | 0.001           | Reference       | <0.001          |
| Male      | 1.226 (1.177–1.278) | <0.001          | 0.889 (0.850–0.931) | <0.001          | 1.093 (1.036–1.153) | 0.001           | 0.918 (0.879–0.958) | <0.001          |
| Histology |                 |                  |                 |                 |
| Adenocarcinoma | Reference | <0.001           | Reference       | <0.001          | Reference       | 0.068           | Reference       | 0.464           |
| Squamous  | 0.650 (0.619–0.682) | <0.001          | 0.457 (0.431–0.484) | <0.001          | 1.058 (0.996–1.124) | 0.068           | 1.019 (0.970–1.070) | 0.464           |
| Tumor Size|                 |                  |                 |                 |
| ≤ 3 cm    | Reference       | <0.001           | Reference       | <0.001          | Reference       | 0.009           | Reference       | <0.001          |
| 3–7 cm    | 1.038 (0.991–1.089) | 0.116           | 1.221 (1.158–1.286) | <0.001          | 1.097 (1.030–1.167) | 0.004           | 1.158 (1.102–1.218) | <0.001          |
| ≥7 cm     | 0.877 (0.824–0.934) | <0.001          | 1.271 (1.186–1.361) | <0.001          | 1.027 (0.947–1.114) | 0.524           | 1.207 (1.132–1.286) | <0.001          |
| N stage   |                 |                  |                 |                 |
| N0        | Reference       | <0.001           | Reference       | <0.001          | Reference       | 0.001           | Reference       | <0.001          |
| N1        | 1.297 (1.195–1.408) | <0.001          | 1.169 (1.069–1.278) | 0.001          | 1.304 (1.110–1.532) | 0.001           | 0.959 (0.877–1.049) | 0.361           |
| N2        | 1.332 (1.264–1.402) | <0.001          | 1.074 (1.014–1.137) | 0.015          | 1.510 (1.362–1.673) | <0.001          | 1.202 (1.138–1.270) | <0.001          |
| N3        | 1.306 (1.229–1.388) | <0.001          | 0.961 (0.899–1.029) | 0.254          | 1.473 (1.304–1.664) | <0.001          | 1.869 (1.755–1.989) | <0.001          |
DISCUSSION

The International Association for the Study of Lung Cancer (IASLC) revised and released the eighth TNM staging system in 2015 (Detterbeck et al., 2016a; Detterbeck et al., 2016b; Detterbeck et al., 2016c; Detterbeck et al., 2016d; Kim, 2016; Travis et al., 2016). According to the 8th TNM staging system, T1 was defined as tumor size ≤ 3 cm, T2 was defined as tumor size of 3–5 cm (including upper limit), T3 was defined as tumor size of 5–7 cm (including upper limit), and T4 was defined as tumor size > 7 cm. In the 7th edition of TNM staging, the tumor size ≤ 3 cm was T1, and the tumor size greater than 7 cm was T3. In our study, we divided into three groups according to tumor size, namely tumor size ≤ 3 cm, ≥ 7 cm and tumor size of 3–7 cm. Our study indicated that patients with a tumor size of 3–7 cm had a tendency to have brain metastasis, liver metastasis and lung metastasis. Meanwhile, the results also demonstrated that patients with a tumor size ≥ 7 cm were more prone to have bone metastasis, brain metastasis, lung metastasis.

Many retrospective studies had shown that tumor size was an important prognostic factor for NSCLC patients (Basaki et al., 2006; Bradley et al., 2002; Dehing-Oberije et al., 2008; Etiz et al., 2002; Stinchcombe et al., 2006). This corresponded to the hypothesis that larger tumors might produce more clonogenic cells, at the same time, it was associated with clinical observation of tumor size and local therapy (Dubben, Thames & Beck-Bornholdt, 1998). Zhang et al. (2015) showed that in patients with early or locally advanced stage NSCLC, as well as in patients with lymph node positive, larger primary tumors were associated with poorer prognosis. In addition, Yang et al. (2010) selected 917 patients who underwent surgery for retrospective analysis, and found that the smaller the tumor, the higher the proportion of N0M0, indicating that the smaller the tumor size, the earlier the staging. A study (Ball et al., 2013) involving 868 NSCLC patients showed that the survival rate of patients with a tumor size ≤ 3 cm was significantly higher than that of patients with a tumor size of 3–7 cm (including upper limit). Interestingly, there was no statistically significant difference between patients with a tumor size > 7 cm and those with tumors greater than 5 cm and less than or equal to 7 cm (P = 0.11), although the former had the highest survival rate (Ball et al., 2013). While, our study drew the conclusion that in patients with brain or lung metastasis, the larger the tumor, the greater the risk of brain or lung metastasis. To a certain extent, it could be considered that different tumor sizes may cause different prognosis. Jin, Chen & Yu (2016) revealed that lymph node involvement in large tumors is higher than in small tumors: the incidence of lymph node metastasis was zero in patients with lesions < 1 cm, 20% in lesions of 1–2 cm, 37.6% in lesions of 2–3 cm, and 66.7% in lesions > 7 cm, which supported the theory that tumor size could embody malignant behavior.

A previous study had reported that liver infiltration was a poor prognostic signal and patients with liver metastasis had significantly lower survival expectations than those with other metastatic diseases (Hoang et al., 2012). In addition, subjects with liver involvement received less clinical benefit from chemotherapy (Castañón et al., 2015). Our study showed no statistically significant difference in the risk of liver metastasis in patients with large tumors. Therefore, we could speculate that small tumors might be controlled by local...
treatment. When the tumor was large, the survival period of the patients was too short to obtain the correlation between tumor size and the risk of liver metastasis due to the limitations of treatment. Previous studies suggested that patients with brain metastases had a good prognosis, probably due to whole brain irradiation in patients with brain metastasis (Gray et al., 2014; Maclean et al., 2013). A univariate analysis displayed that pulmonary metastasis was not an independent prognostic factor in NSCLC patients (Tamura et al., 2015). Homogeneous risk factors for morbidity and survival outcomes in NSCLC patients with bone metastasis included male (OR 0.815, 95% CI [0.771–0.861], \( P < 0.001 \)) and higher T-stage (OR 1.287, 95% CI [1.251–1.324], \( P < 0.001 \)). In addition, these clinical factors were able to be combined with biomarkers to more accurately predict bone metastasis in NSCLC patients, contributing to the early diagnosis and early intervention of bone metastasis (Song et al., 2019).

Lung cancer was a heterogeneous disease, with different subtypes showing different genetic variation. Also, different subtypes also had their own specific variants, such as MET in adenocarcinoma, FGFR1 and FGFR3 in squamous cell carcinoma and MYC in small cell lung cancer (Zhang et al., 2017). This might explain the different proportion of metastatic sites in different NSCLC subtypes with the same tumor size in this study. Secondly, the abnormality of epigenetics would lead to intratumoral heterogeneity, which could also be the cause of the above results (Dong et al., 2017). In addition, Xu et al. (2017) found that the expression of different kinds of mucins in lung cancer subtypes led to inter-tumor heterogeneity, which could also be one of the reasons. Unfortunately, due to the lack of access to such information in the database, this study had not carried out the analysis of tumor biology, which needed to be verified and improved by prospective researches.

The advantage of this study was that the sample size was relatively large, and by extracting data from the SEER database, the relationship between tumor size and metastasis sites in stage IV NSCLC patients was well analyzed. Inevitably, there were some limitations in our study. Firstly, as a retrospective study, although the sample size was relatively large, we could not avoid selection bias. Secondly, other variables, such as smoking history, mutation status, performance status, and treatment strategies that might affect prognosis were not included in this study. In addition, we did not collect information for other metastatic sites, such as adrenal glands, which might lead to underestimation of other metastatic sites. Therefore, a series of prospective studies are needed to verify these conclusions.

**CONCLUSIONS**

There was statistical significance between tumor size and metastatic site in patients with stage IV NSCLC. For brain or lung metastasis, the larger the tumor, the more likely it was to develop metastasis. For liver metastasis, patients with a tumor size of 3–7 cm were more prone to develop liver metastasis. For bone metastasis, patients with a tumor size \( \geq 7 \) cm were more likely to have bone metastasis.
ADDITIONAL INFORMATION AND DECLARATIONS

Funding
Haiyong Wang and Zhehai Wang were funded by the Special Funds for Taishan Scholars Project (Grant No. tsqn201812149) and the Shandong Province Key R&D Plan (Grant No. 2018GSF119014). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Grant Disclosures
The following grant information was disclosed by the authors:
Special Funds for Taishan Scholars Project: tsqn201812149.
Shandong Province Key R&D Plan: 2018GSF119014.

Competing Interests
The authors declare there are no competing interests.

Author Contributions
• Qinge Shan and Yanling Fan performed the experiments, authored or reviewed drafts of the paper, approved the final draft.
• Jun Guo analyzed the data, contributed reagents/materials/analysis tools, prepared figures and/or tables, authored or reviewed drafts of the paper, approved the final draft.
• Xiao Han analyzed the data, prepared figures and/or tables, authored or reviewed drafts of the paper, approved the final draft.
• Haiyong Wang conceived and designed the experiments, prepared figures and/or tables, approved the final draft.
• Zhehai Wang conceived and designed the experiments, prepared figures and/or tables, authored or reviewed drafts of the paper, approved the final draft.

Data Availability
The following information was supplied regarding data availability:
The raw measurements are available in Data S1.

Supplemental Information
Supplemental information for this article can be found online at http://dx.doi.org/10.7717/peerj.7822#supplemental-information.

REFERENCES
Badawy AA, Khedr G, Omar A, Bae S, Arafat W, Grant S. 2018. Site of metastases as prognostic factors in unselected population of stage IV Non-small cell lung cancer. Asian Pacific Journal of Cancer Prevention 19(7):1907–1910 DOI 10.22034/APJCP.2018.19.7.1907.
Ball D, Mitchell A, Giroux D, Rami-Porta R, IASLC Staging Committee and Participating Institutions. 2013. Effect of tumor size on prognosis in patients treated with radical radiotherapy or chemoradiotherapy for non–small cell lung cancer. An analysis of the staging project database of the international association for the study of lung cancer. *Journal of Thoracic Oncology* 8(3):315–321 DOI 10.1097/JTO.0b013e31827dc74d.

Basaki K, Abe Y, Aoki M, Kondo H, Hatayama Y, Nakaji S. 2006. Prognostic factors for survival in stage III non–small-cell lung cancer treated with definitive radiation therapy: impact of tumor volume. *International Journal of Radiation Oncology, Biology, Physics* 64(2):449–454 DOI 10.1016/j.ijrobp.2005.07.967.

Bradley JD, Ieumwananonthachai N, Purdy JA, Wasserman TH, Lockett MA, Graham MV, Perez CA. 2002. Gross tumor volume, critical prognostic factor in patients treated with three-dimensional conformal radiation therapy for non–small-cell lung carcinoma. *International Journal of Radiation Oncology, Biology, Physics* 52(1):49–57 DOI 10.1016/S0360-3016(01)01772-2.

Cancer Council Australia Lung Cancer Guidelines Working Party. 2016. Clinical practice guidelines for the treatment of lung cancer. Available at http://wiki.cancer.org.au/australia/Guidelines:Lung cancer (accessed on 22 April 2016).

Castañón E, Rolfo C, Vinal D, López I, Fusco JP, Santisteban M, Martin P, Zubiri L, Echeveste JI, Gil-Bazo I. 2015. Impact of epidermal growth factor receptor (EGFR) activating mutations and their targeted treatment in the prognosis of stage IV non–small cell lung cancer (NSCLC) patients harboring liver metastasis. *Journal of Translational Medicine* 13:257 DOI 10.1186/s12967-015-0622-x.

Dehing-Oberije C, De Ruysscher D, Van der Weide H, Hochstenbag M, Bootsma G, Geraedts W, Pitz C, Simons J, Teule J, Rahmy A, Thimister P, Steck H, Lambin P. 2008. Tumor volume combined with number of positive lymph node stations is a more important prognostic factor than TNM stage for survival of non–small cell lung cancer patients treated with (chemo)radiotherapy. *International Journal of Radiation Oncology, Biology, Physics* 70(4):1039–1044 DOI 10.1016/j.ijrobp.2007.07.2323.

Detterbeck FC, Bolejack V, Arenberg DA, Crowley J, Donington JS, Franklin WA, Girard N, Marom EM, Mazzone PJ, Nicholson AG, Rusch VW, Tanoue LT, Travis WD, Asamura H, Rami-Porta R, IASLC Staging and Prognostic Factors Committee; Advisory Boards; Multiple Pulmonary Sites Workgroup; Participating Institutions. 2016a. The IASLC lung cancer staging project: background data and proposals for the classification of lung cancer with separate tumor Nodules in the forthcoming eighth edition of the TNM classification for lung cancer. *Journal of Thoracic Oncology* 11(5):681–692 DOI 10.1016/j.jtho.2015.12.114.

Detterbeck FC, Chansky K, Groome P, Bolejack V, Crowley J, Shemanski L, Kennedy C, Krasnik M, Peake M, Rami-Porta R, IASLC Staging and Prognostic Factors Committee, Advisory Boards, and Participating Institutions. 2016b. The IASLC lung cancer staging project: methodology and validation used in the development of proposals for revision of the stage classification of NSCLC in the forthcoming
Detterbeck FC, Franklin WA, Nicholson AG, Girard N, Arenberg DA, Travis WD, Mazzone PJ, Marom EM, Donington JS, Tanoue LT, Rusch VW, Asamura H, Rami-Porta R, IASLC Staging and Prognostic Factors Committee; Advisory Boards; Multiple Pulmonary Sites Workgroup. 2016c. The IASLC lung cancer staging project: background data and proposed criteria to distinguish separate primary lung cancers from metastatic foci in patients with two lung tumors in the forthcoming eighth edition of the TNM classification for lung cancer. *Journal of Thoracic Oncology* 11(5):651–665 DOI 10.1016/j.jtho.2016.01.025.

Detterbeck FC, Nicholson AG, Franklin WA, Marom EM, Travis WD, Girard N, Arenberg DA, Bolejack V, Donington JS, Mazzone PJ, Tanoue LT, Rusch VW, Crowley J, Asamura H, Rami-Porta R, IASLC Staging and Prognostic Factors Committee; Advisory Boards; Multiple Pulmonary Sites Workgroup; Participating Institutions. 2016d. The IASLC lung cancer staging project: summary of proposals for revisions of the classification of lung cancers with multiple pulmonary sites of involvement in the forthcoming eighth edition of the TNM classification. *Journal of Thoracic Oncology* 11(5):639–650 DOI 10.1016/j.jtho.2016.01.024.

Dong N, Shi L, Wang DC, Chen C, Wang X. 2017. Role of epigenetics in lung cancer heterogeneity and clinical implication. *Seminars in Cell & Developmental Biology* 64:18–25 DOI 10.1016/j.semcdb.2016.08.029.

Dubben HH, Thames HD, Beck-Bornholdt HP. 1998. Tumor volume: a basic and specific response predictor in radiotherapy. *Radiotherapy and Oncology* 47(2):167–174 DOI 10.1016/S0167-8140(97)00215-6.

Etiz D, Marks LB, Zhou SM, Bentel GC, Clough R, Hernando ML, Lind PA. 2002. Influence of tumor volume on survival in patients irradiated for non-small-cell lung cancer. *International Journal of Radiation Oncology, Biology, Physics* 53(4):835–846 DOI 10.1016/S0360-3016(02)02814-6.

Govindan R, Page N, Morgensztern D, Read W, Tierney R, Vlahiotis A, Spitznagel EL, Piccirillo J. 2006. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. *Journal of Clinical Oncology* 24(28):4539–4544 DOI 10.1200/JCO.2005.04.4859.

Gray PJ, Mak RH, Yeap BY, Cryer SK, Pinnell NE, Christianson LW, Sher DJ, Arvold ND, Baldini EH, Chen AB, Kozono DE, Swanson SJ, Jackman DM, Alexander BM. 2014. Aggressive therapy for patients with non-small cell lung carcinoma and synchronous brain-only oligometastatic disease is associated with long-term survival. *Lung Cancer* 85(2):239–244 DOI 10.1016/j.lungcan.2014.06.001.

Hoang T, Dahlberg SE, Sandler AB, Brahmer JR, Schiller JH, Johnson DH. 2012. Prognostic models to predict survival in non-small-cell lung cancer patients treated with first-line paclitaxel and carboplatin with or without bevacizumab. *Journal of Thoracic Oncology* 7(9):1361–1368 DOI 10.1097/JTO.0b013e318260e106.
Jin Y, Chen M, Yu XM. 2016. Comparison of the 7th and proposed 8th editions of the AJCC/UICC TNM staging system for non-small cell lung cancer undergoing radical surgery. Scientific Reports 6:33587 DOI 10.1038/srep33587.

Kim SS. 2016. The IASLC lung cancer staging project proposal for the classification of lung cancers with multiple pulmonary sites of involvement: the first step toward finding optimal treatment. Journal of Thoracic Disease 8(9):2313–2314 DOI 10.21037/jtd.2016.08.28.

Lee DS, Kim YS, Kay CS, Kim SH, Yeo CD, Kim JW, Kim SJ, Kim YK, Ko YH, Kang JH, Lee KY. 2016. Distinctive patterns of initially presenting metastases and clinical outcomes according to the histological subtypes in stage IV non-small cell lung cancer. Medicine 95(6):e2795 DOI 10.1097/MD.0000000000002795.

Maclean J, Fersht N, Singhera M, Mulholl P, McKee O, Kitchen N, Short SC. 2013. Multi-disciplinary management for patients with oligometastases to the brain: results of a 5 year cohort study. Radiation Oncology 8:156 DOI 10.1186/1748-717X-8-156.

Molina JR, Yang P, Cassivi SD, Schild SE, Adjei AA. 2008. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clinic Proceedings 83(5):584–594 DOI 10.1016/S0025-6196(11)60735-0.

Morgensztern D, Waqar S, Subramanian J, Gao F,Govindan R. 2009. Improving survival for stage IV non-small cell lung cancer: a surveillance, epidemiology, and end results survey from 1990 to 2005. Journal of Thoracic Oncology 4(12):1524–1529 DOI 10.1097/JTO.0b013e3181ba3634.

Motta G, Carbone E, Spinelli E, Nahum MA, Testa T, Flocchini GP. 1999. Consideration about tumor size as a factor of prognosis in NSCLC. Annali Italiani di Chirurgia 70(6):893–897.

Saad AG, Yeap BY, Thunnissen FB, Pinkus GS, Pinkus JL, Loda M, Sugarbaker DJ, Johnson BE, Chirieac LR. 2008. Immunohistochemical markers associated with brain metastases in patients with nonsmall cell lung carcinoma. Cancer 113(8):2129–2138 DOI 10.1002/cncr.23826.

Saad F, Lipton A, Cook R, Chen YM, Smith M, Coleman R. 2007. Pathologic fractures correlate with reduced survival in patients with malignant bone disease. Cancer 110(8):1860–1867 DOI 10.1002/cncr.22991.

Shepherd FA, Crowley J, Van Houtte P, Postmus PE, Carney D, Chansky K, Shaikh Z, Gold straw P, International Association for the Study of Lung CancerInternational Staging Committee and Participating Institutions. 2007. The international association for the study of lung cancer lung cancer staging project: proposals regarding the clinical staging of small cell lung cancer in the forthcoming (seventh) edition of the tumor, node, metastasis classification for lung cancer. Journal of Thoracic Oncology 2(12):1067–1077 DOI 10.1097/JTO.0b013e31815bdc0d.

Siegel RL, Miller KD, Jemal A. 2018. Cancer statistics, 2018. CA: A Cancer Journal for Clinicians 68(1):7–30.

Song Q, Shang J, Zhang C, Zhang L, Wu X. 2019. Impact of the homogeneous and heterogeneous risk factors on the incidence and survival outcome of bone metastasis in
NSCLC patients. *Journal of Cancer Research and Clinical Oncology* **145**(3):737–746 DOI 10.1007/s00432-018-02826-7.

Stinchcombe TE, Morris DE, Moore DT, Bechtel JH, Halle JS, Mears A, Deschesne K, Rosenman JG, Socinski MA. 2006. Post-chemotherapy gross tumor volume is predictive of survival in patients with stage III non-small cell lung cancer treated with combined modality therapy. *Lung Cancer* **52**(1):67–74 DOI 10.1016/j.lungcan.2005.11.008.

Surveillance, Epidemiology, and End Results (SEER) Program. 2018. SEER*Stat database: incidence-SEER 9 regs research data, 2018 Sub (1975–2016) <Katrina/Rita population adjustment >-linked to county attributes - total U.S., 1969–2017 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, released 2019, based on the 2018 submission. Available at [http://www.seer.cancer.gov](http://www.seer.cancer.gov).

Tamura T, Kurishima K, Nakazawa K, Kagohashi K, Ishikawa H, Satoh H, Hizawa N. 2015. Specific organ metastases and survival in metastatic non-small-cell lung cancer. *Molecular and Clinical Oncology* **3**(1):217–221 DOI 10.3892/mco.2014.410.

Travis WD, Asamura H, Bankier AA, Beasley MB, Detterbeck F, Flieder DB, Goo JM, MacMahon H, Naidich D, Nicholson AG, Powell CA, Prokop M, Rami-Porta R, Rusch V, Van Schil P, Yatabe Y, International Association for the Study of Lung Cancer Staging and Prognostic Factors Committee and Advisory Board Members. 2016. The IASLC lung cancer staging project: proposals for coding T categories for Subsolid Nodules and assessment of tumor size in part-solid tumors in the forthcoming eighth edition of the TNM classification of lung cancer. *Journal of Thoracic Oncology* **11**(8):1204–1223 DOI 10.1016/j.jtho.2016.03.025.

Tsuya A, Kurata T, Tamura K, Fukuoka M. 2007. Skeletal metastases in non-small cell lung cancer: a retrospective study. *Lung Cancer* **57**(2):229–232 DOI 10.1016/j.lungcan.2007.03.013.

Xu M, Wang DC, Wang X, Zhang Y. 2017. Correlation between mucin biology and tumor heterogeneity in lung cancer. *Seminars in Cell & Developmental Biology* **64**:73–78 DOI 10.1016/j.semcdb.2016.08.027.

Yang F, Chen H, Xiang J, Zhang Y, Zhou J, Hu H, Zhang J, Luo X. 2010. Relationship between tumor size and disease stage in non-small cell lung cancer. *BMC Cancer* **10**:474 DOI 10.1186/1471-2407-10-474.

Zhang J, Gold KA, Lin HY, Swisher SG, Xing Y, Lee JJ, Kim ES, William Jr WN. 2015. Relationship between tumor size and survival in non-small-cell lung cancer (NSCLC): an analysis of the surveillance, epidemiology, and end results (SEER) registry. *Journal of Thoracic Oncology* **10**(4):682–690 DOI 10.1097/JTO.0000000000000456.

Zhang Y, Wang DC, Shi L, Zhu B, Min Z, Jin J. 2017. Genome analyses identify the genetic modification of lung cancer subtypes. *Seminars in Cancer Biology* **42**:20–30 DOI 10.1016/j.semcancer.2016.11.005.